Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.

Hologic, Inc. (Marlborough, MA, USA) has entered into a definitive agreement to acquire Endomagnetics Ltd. (Cambridge, UK), a privately held developer of breast cancer surgery technologies, for approximately USD 310 million, subject to working capital and other customary closing adjustments.

Endomag develops and sells breast surgery localization and lymphatic tracing technologies. Its products include the Magseed marker for magnetic tissue localization before surgery and the Magtrace lymphatic tracing injectable for breast cancer staging. At the heart of Endomag’s product platform is the Sentimag localization system, a non-radioactive surgical guidance platform that offers both tissue localization and breast cancer staging in one platform. The Sentimag uses a probe that works like a metal detector and is used to detect Endomag’s magnetic seed (Magseed) and liquid tracer (Magtrace) for removing tumors and performing minimally invasive staging procedures.

Hologic is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections, and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

“Endomag’s suite of solutions complements our existing breast surgery portfolio and will provide surgeons and radiologists with an expanded range of options to meet the individual needs of more patients undergoing critical breast cancer procedures,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic. “With a global footprint and a similar commitment to women’s health, we are excited about the potential of welcoming the Endomag team and our future opportunities together to increase access to these technologies and better serve patients across the breast health continuum of care.”

“We are delighted to attract the strength and focus of Hologic to power the next phase of our growth,” said Eric Mayes, CEO of Endomag. “Our team is encouraged by our cultural alignment and the potential to strengthen a broader portfolio of solutions to improve women’s health globally.”